Loading...

CLRB CELLECTAR BIOSCIENCES INC Other Situations 8-K Filing

CLLC

CLRB

CELLECTAR BIOSCIENCES INC

(CLRB)

2024 8-K

Show Summary

Show Summary

Reverse Stock Split

Warrant Exercise

Financial Statements

Management Changes

Financial Results

Nasdaq Compliance Notice

Strategic Initiatives

Workforce Reduction

Q3 2024 Results

Consent Correction

Nasdaq Compliance

Q2 2024 Results

Restatement of Financial St...

Financial Condition

Warrant Exercise Inducement...

Accountant Change

Lease Agreement

Annual Meeting Approval

Earnings Reports

Financial Results Announcement

Notice from Nasdaq

Financial Results Announcement

Amendment to Certificate of...

Private Placement Offering

Financial Results Announcement

Data from Study of iopofosi...

Annual Meeting of Stockholders

Adjourned Meeting of Stockh...

Financial Results Announcement

Financial Results Announcement

Lease Agreement

External Links:

Cellectar Biosciences issued a press release on January 8, 2024, announcing positive topline data from its clinical trial for Iopofosine I 131 in Waldenstrom's Macroglobulinemia.

AI Assistant

CELLECTAR BIOSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.